Analysts Set Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) Price Target at $31.33

Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE) has been given a consensus recommendation of “Moderate Buy” by the nine research firms that are currently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has issued a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price target among analysts that have covered the stock in the last year is $31.3333.

GLUE has been the topic of a number of research reports. Guggenheim boosted their target price on shares of Monte Rosa Therapeutics from $16.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, January 8th. Wells Fargo & Company lifted their price target on shares of Monte Rosa Therapeutics from $22.00 to $30.00 and gave the stock an “overweight” rating in a research report on Thursday, January 8th. Zacks Research downgraded Monte Rosa Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday. Weiss Ratings reissued a “sell (d)” rating on shares of Monte Rosa Therapeutics in a research note on Monday, December 29th. Finally, Jefferies Financial Group restated a “buy” rating and issued a $31.00 target price on shares of Monte Rosa Therapeutics in a report on Wednesday, January 7th.

Monte Rosa Therapeutics Stock Up 3.4%

Shares of GLUE stock opened at $19.55 on Thursday. The stock has a 50-day simple moving average of $19.29 and a 200 day simple moving average of $12.17. The stock has a market capitalization of $1.27 billion, a P/E ratio of 61.10 and a beta of 1.61. Monte Rosa Therapeutics has a fifty-two week low of $3.50 and a fifty-two week high of $25.77.

Monte Rosa Therapeutics (NASDAQ:GLUE) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.33) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.06. Monte Rosa Therapeutics had a net margin of 11.54% and a return on equity of 8.28%. The firm had revenue of $12.77 million for the quarter, compared to analysts’ expectations of $7.37 million. On average, sell-side analysts anticipate that Monte Rosa Therapeutics will post -1.49 earnings per share for the current year.

Insiders Place Their Bets

In other Monte Rosa Therapeutics news, CEO Markus Warmuth sold 5,466 shares of the business’s stock in a transaction dated Wednesday, January 7th. The stock was sold at an average price of $23.49, for a total transaction of $128,396.34. Following the sale, the chief executive officer owned 618,937 shares in the company, valued at approximately $14,538,830.13. The trade was a 0.88% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in GLUE. ProShare Advisors LLC grew its stake in Monte Rosa Therapeutics by 11.8% during the 4th quarter. ProShare Advisors LLC now owns 11,374 shares of the company’s stock valued at $178,000 after acquiring an additional 1,199 shares in the last quarter. Baader Bank Aktiengesellschaft acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth approximately $172,000. Strs Ohio acquired a new stake in shares of Monte Rosa Therapeutics during the fourth quarter worth approximately $566,000. Vanguard Group Inc. grew its position in Monte Rosa Therapeutics by 8.6% during the fourth quarter. Vanguard Group Inc. now owns 3,246,500 shares of the company’s stock valued at $50,905,000 after purchasing an additional 257,547 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Monte Rosa Therapeutics by 32.5% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,164 shares of the company’s stock valued at $50,000 after buying an additional 776 shares during the period. 79.96% of the stock is owned by hedge funds and other institutional investors.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a biotechnology company focused on accelerating drug discovery through the integration of single-cell genomics and artificial intelligence. Founded in 2020 and headquartered in Cambridge, Massachusetts, the company has built a proprietary platform designed to identify novel therapeutic targets and optimize lead candidates for areas of high unmet medical need. By combining cutting-edge computational methods with comprehensive cellular profiling, Monte Rosa aims to streamline the preclinical development process and uncover insights into disease biology that might otherwise remain hidden.

The company’s main business activities center on using its AI-driven discovery engine to pursue programs in immuno-oncology and neuroscience.